Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS

Share :
Published: 7 Feb 2023
Views: 60
Prof Laura Dawson - University of Toronto, Toronto, Canada

Prof Laura Dawson speaks to ecancer about her randomised phase III study of sorafenib vs. SBRT followed by sorafenib in hepatocellular carcinoma.

The study investigated if SBRT followed by sorafenib (SBRT/S) improves overall survival (OS), progression-free survival (PFS) and quality of life (QOL) vs. sorafenib alone (S), in patients with HCC.

Compared to sorafenib alone, SBRT improved OS & PFS in patients with HCC, with no observed increase in adverse events, and a strong suggestion for QOL benefit at 6 months. Prof Dawson concludes by talking about the clinical impact of these results.